Isis Pharmaceuticals, Inc.

Ibis Biosciences, Inc.

Regulus Therapeutics Inc.

Leidos, Inc.

Ionis Pharmaceuticals, Inc.

Isis Pharmacueticals, Inc.

Richard Holmes Griffey

Steven A Hofstadler

Eric E Swayze

David J Ecker

John McNeil

Stanley T Crooke

Rangarajan Sampath

Susan M Freier

C Frank Bennett

Balkrishen Bhat

Brenda F Baker

Thomas A Hall

Lawrence B Blyn

Muthiah Manoharan

Charles Allerson

Anne Bettina Eldrup

John Dresios

Jared James Drader

Michael T Migawa

James C Hannis

Thazha P Prakash

Xiaojing Wang

Venkatraman Mohan

Vasulinga T Ravikumar

Douglas L Cole

Mark W Eshoo

Ravi Jain

Stephen Hanessian

Susanta Sekhar Adhikari

Bridget Lollo

Yun Jiang

Vivek Samant

Kandasamy Pachamuthu

Janek Szychowski

Eric G Marcusson

Timothy A Vickers

Howard W Walker

William Leslie Hicks

Eric Matthew Amendt

Prasad Dande

Henri M Sasmor

Neill K White

Yili Ding

Challise J Sullivan

Erik D Pendleton

Raymond Ranken

Phillip Dan Cook

Punit P Seth

Andrew Mamoru Kawasaki

Newell Convers Wyeth

Thomas W Bruice

Charles John Guinosso

Christine Esau

Erich Koller

Elizabeth Anne Jefferson

John Paul Ziegler

Kristin Sannes Lowery

Lendell L Cummins

G Susan Srivatsa

Ray Ranken

Ranga Sampath

Eigen Peralta

Martin A Maier

Roland Stoughton

Garth A Kinberger

Ranjan Perera

Kristin Sannes-Lowery

Bryan A Kraynack

Jonathan R Bar-on

Scott Stewart

Ann B Eldrup

Bridget Gordon

Stephen A Hofstadler

Stanley T Crook

Steve Hofstadler

Dino J Sofianos

Karl H Rudnick

Duane J Knize

Cecil L Basham, Jr

Neil White

Clifford T Lewis

John P Penhune

David W Robbins

Dennis P Murray

Brons M Larson

Anne B Eldrup

A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements. Protein synthesis and purification modules are integrated into self-contained disposable fluidic cartridge that eliminates cross-contamination between runs. The platform allows for flexible production of protein biologics within 24 hours (from DNA to purified product).

Portable fluidic platform for rapid cell-free production of protein biologics

The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.

Compositions comprising alternating 2'-modified nucleosides for use in gene modulation

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

Marine vessel propulsor occlusion systems and devices made of novel fabrics formed from biodegradable and/or dissolvable materials, and methods of manufacturing and using the same are disclosed. The propulsor occlusion devices can slow and/or incapacitate a marine vessel without serious injury to occupants and without destroying the vessel's propulsion system.

Material for propeller occlusion of marine vessels

The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.

Methods and compositions for wound treatment

Oligonucleotide compositions comprising first and second oligonucleotides are provided wherein at least a portion of the first oligonucleotide is capable of hybridizing with at least a portion of the second oligonucleotide, at least a portion of the first oligonucleotide is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligonucleotides includes at least one nucleotide having a modified phosphorous-containing internucleoside linkage. Oligonucleotide/protein compositions are also provided comprising an oligonucleotide complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligonucleotide has a modified phosphorous-containing internucleoside linkage.

Phosphorous-linked oligomeric compounds and their use in gene modulation

The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.

Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy

The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.

Methods for rapid identification of pathogens in humans and animals

Growing community of inventors

Vista, CA, United States of America

Richard Holmes Griffey